Last Saturday, Denis Belitškin defended his Ph.D. thesis. The topic was The role of type II serine protease hepsin in breast cancer signaling.

Last week, with a delay of 2.5 years, the GeneCellNano flagship partners finally met for the first time in real life.

Last week I failed to explain the difference between risk and hazard. Perhaps because the distinction does not exist that clearly in my mother tongue (German).